Evidence map›Paper›PMID 40676173›Full record

ArticleBone marrow transplantation2025

Characteristics and prognosis of central nervous system relapse after allogeneic hematopoietic stem cell transplantation in adult patients with leukemia.

Li-Ping Guo, Li-Juan Hu, Xiao-Dong Mo, Yu-Qian Sun, Yi-Fei Cheng, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Yu Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Li-Ping GuoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Li-Juan HuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Xiao-Dong MoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.ORCID 0000-0002-9881-7945
Yu-Qian SunPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.ORCID 0000-0003-1856-2231
Yi-Fei ChengPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Lan-Ping XuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.ORCID 0000-0002-0267-1081
Xiao-Hui ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.ORCID 0000-0003-4730-256X
Xiao-Jun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.ORCID 0000-0002-2145-6643
Yu WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China. ywyw3172@sina.com.ORCID 0000-0003-1253-7465

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system(CNS) is a common site of extramedullary involvement after allogeneic hematopoietic stem cell transplantation(allo-HSCT). It may confer inferior survival when combined with bone marrow(BM) relapse in leukemia patients. We performed a retrospective study to investigate the associated risk factors and prognosis in adult patients with post-transplant CNS relapse. Between 2016 and 2024 in our center, 74 leukemia patients developed CNS relapse after allo-HSCT, with 23 cases of isolated CNS(iCNS) relapse and 51 cases of combined CNS and BM(CNS&BM) relapse. Patients with CNS&BM relapse after allo-HSCT conferred inferior 5-year overall survival (OS) compared with those with iCNS relapse, and independent risk factors related with CNS&BM relapse were identified, including male gender(relative risk ratio[RR] = 4.09, 95% confidence interval [CI] = 1.29-13.02, p = 0.017), HLA-identical transplantation (RR = 4.11, 95% CI = 1.10-15.32, p = 0.035), and without chronic graft-versus-host disease occurrence (RR = 3.73, 95% CI = 1.00-13.84, p = 0.049). Early CNS relapse was identified as an independent predictor of worse 5-year OS from HSCT for patients with CNS&BM relapse (n = 51, <12 months after allo-HSCT, hazard ratio=7.35, p = 0.003). Systemic therapy after CNS relapse reduced subsequent BM relapse for ALL and CML patients (p = 0.038). These findings demonstrate the outcome of patients with post-transplant CNS&BM relapse remains very poor. HLA-haploindentical allo-HSCT and systemic therapy after CNS relapse may better reduce BM relapse.

Indexed as

Central Nervous System NeoplasmsHematopoietic Stem Cell TransplantationLeukemiaAdolescentAdultAgedFemaleHumansMaleMiddle AgedPrognosisRecurrenceRetrospective StudiesRisk FactorsTransplantation, HomologousYoung Adult

Identifiers

PMID40676173

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.